News

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best ...
Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...
Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.
Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18. INSM has a 100% “Buy” opinion from ...
Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment ...
The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...
The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...
Jefferies analyst Kelly Shi maintained a Buy rating on Insmed today and set a price target of $148.00. The company’s shares closed today at $122.00. Elevate Your Investing Strat ...
Devarakonda covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Scholar Rock Holding, and Incyte. According to TipRanks, Devarakonda has an average return of -2.8% and a 37.04 ...
Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...
The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...